Tiziana Life Sciences Ltd. (NASDAQ: TLSA) reported initial results from two patients with Multiple System Atrophy (MSA) treated with its intranasal foralumab therapy in a Phase 2 clinical trial.

PET scan analysis showed reductions in inflammatory activity in brain regions affected by MSA following treatment with the intranasal anti-CD3 monoclonal antibody. The first two patients demonstrated up to approximately 35% reduction in standardized uptake value and approximately 24% reduction in standardized uptake value ratio in affected brain areas.

The reductions occurred in the basal ganglia and cerebellar white matter regions, which are involved in the neurodegenerative processes of MSA. PET imaging comparisons conducted before and after treatment showed decreased radiotracer uptake across several disease-relevant brain regions.

"These early PET imaging findings provide quantitative evidence supporting the biological activity of intranasal foralumab in patients with MSA," said Tarun Singhal, Founding Director of the NeuroPET Program at Brigham and Women's Hospital. "Based on the available data, these appear to be robust quantitative findings and are comparable to results previously observed in patients with multiple sclerosis treated with intranasal foralumab."

MSA is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia. No approved disease-modifying treatments currently exist for the condition.

Intranasal foralumab is described by the company as designed to modulate the immune system through mucosal tolerance mechanisms and reduce inflammation without systemic toxicities associated with traditional anti-CD3 therapies. The therapy has previously shown inflammation reduction in patients with multiple sclerosis and Alzheimer's disease according to the company.

Tiziana plans to continue evaluating intranasal foralumab in additional patients to validate these findings and characterize the therapy's potential in MSA treatment.